Advertisement

Journal of Molecular Neuroscience

, Volume 55, Issue 4, pp 872–879 | Cite as

Resveratrol Attenuates the Blood-Brain Barrier Dysfunction by Regulation of the MMP-9/TIMP-1 Balance after Cerebral Ischemia Reperfusion in Rats

  • Haidong Wei
  • Shiquan Wang
  • Luming Zhen
  • Qianzi Yang
  • Zhixin Wu
  • Xiaoming Lei
  • Jianrui Lv
  • Lize XiongEmail author
  • Rongliang XueEmail author
Article

Abstract

The collapse of the blood-brain barrier (BBB) is one of the fundamental pathophysiology changes during cerebral ischemia reperfusion injury. Resveratrol has been recently reported to reduce cerebral ischemic damage by regulating the matrix metalloproteinase-9 (MMP-9). But, more direct evidence for the explanation of the BBB protected by resveratrol against cerebral ischemia reperfusion is still lacking. Therefore, the present study was aimed to investigate the regulation of BBB integrity by resveratrol after cerebral ischemia reperfusion and to determine the role of the MMP-9 and its endogenous inhibitor TIMP-1 balance in this process. Cerebral ischemia was induced by middle cerebral artery occlusion in rats. The BBB function was evaluated by brain water content and the Evans blue dye extravasation; the activities of MMP-9 and TIMP-1 were detected by using gelatin zymography analysis, and cellular apoptosis was examined by TUNEL staining. We confirmed that resveratrol reduced the cerebral ischemia reperfusion damage, brain edema, and Evans blue dye extravasation. Moreover, we found that resveratrol improved the balance of MMP-9/TIMP-1 in terms of their expressions and activities. A TIMP-1 neutralizing antibody reversed those neuroprotective effects of resveratrol. In conclusion, resveratrol attenuated the cerebral ischemia by maintaining the integrity of BBB via regulation of MMP-9 and TIMP-1.

Keywords

Resveratrol Cerebral ischemia Blood-brain barrier Matrix metalloproteinase Tissue inhibitor of metalloproteinase 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant No. 43411C1071), the Changjiang Scholars and Innovative Research Team in University (Grant IRT1053), and the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (Grant 2012BA111B02). The authors greatly appreciate the help provided by Miss Yaoying Yu and thank Dr. Bairen Wang for carefully reading the manuscript.

Supplementary material

12031_2014_441_Fig6_ESM.gif (121 kb)
ESM 1

(GIF 121 kb)

12031_2014_441_MOESM1_ESM.tif (8.2 mb)
High resolution image (TIFF 8354 kb)

References

  1. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7(1):41–53CrossRefPubMedGoogle Scholar
  2. Asahi M, Asahi K, Jung JC, Del ZG, Fini ME, Lo EH (2000) Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20(12):1681–1689CrossRefPubMedGoogle Scholar
  3. Ashwal S, Tone B, Tian HR, Cole DJ, Pearce WJ (1998) Core and penumbral nitric oxide synthase activity during cerebral ischemia and reperfusion. Stroke 29(5):1037–1046, 1047CrossRefPubMedGoogle Scholar
  4. Belayev L, Busto R, Ikeda M, Rubin LL, Kajiwara A, Morgan L, Ginsberg MD (1998) Protection against blood–brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study. Brain Res 787(2):277–285CrossRefPubMedGoogle Scholar
  5. Belayev L, Busto R, Zhao W, Fernandez G, Ginsberg MD (1999) Middle cerebral artery occlusion in the mouse by intraluminal suture coated with poly-L-lysine: neurological and histological validation. Brain Res 833(2):181–190CrossRefPubMedGoogle Scholar
  6. Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477(1–2):267–283CrossRefPubMedGoogle Scholar
  7. Chen HY, Chen TY, Lee MY, Chen ST, Hsu YS, Kuo YL, Chang GL, Wu TS, Lee EJ (2006) Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood-brain barrier permeability after transient focal cerebral ischemia in mice. J Pineal Res 41(2):175–182CrossRefPubMedGoogle Scholar
  8. Chen F, Radisky ES, Das P, Batra J, Hata T, Hori T, Baine AM, Gardner L, Yue MY, Bu G, Del ZG, Patel TC, Nguyen JH (2013) TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure. J Cereb Blood Flow Metab 33(7):1041–1049CrossRefPubMedCentralPubMedGoogle Scholar
  9. Cheng G, Zhang X, Gao D, Jiang X, Dong W (2009) Resveratrol inhibits MMP-9 expression by up-regulating PPAR alpha expression in an oxygen glucose deprivation-exposed neuron model. Neurosci Lett 451(2):105–108CrossRefPubMedGoogle Scholar
  10. Desilles JP, Rouchaud A, Labreuche J, Meseguer E, Laissy JP, Serfaty JM, Lapergue B, Klein IF, Guidoux C, Cabrejo L, Sirimarco G, Lavallee PC, Schouman-Claeys E, Amarenco P, Mazighi M (2013) Blood-brain barrier disruption is associated with increased mortality after endovascular therapy. Neurology 80(9):844–851CrossRefPubMedGoogle Scholar
  11. Dong W, Gao D, Lin H, Zhang X, Li N, Li F (2008) New insights into mechanism for the effect of resveratrol preconditioning against cerebral ischemic stroke: Possible role of matrix metalloprotease-9. Med Hypotheses 70(1):52–55CrossRefPubMedGoogle Scholar
  12. Dziembowska M, Wlodarczyk J (2012) MMP9: a novel function in synaptic plasticity. Int J Biochem Cell Biol 44(5):709–713CrossRefPubMedGoogle Scholar
  13. Fujimoto M, Takagi Y, Aoki T, Hayase M, Marumo T, Gomi M, Nishimura M, Kataoka H, Hashimoto N, Nozaki K (2008) Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. J Cereb Blood Flow Metab 28(10):1674–1685CrossRefPubMedGoogle Scholar
  14. Garcia JH, Wagner S, Liu KF, Hu XJ (1995) Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. statistical validation. Stroke 26(4):627–634, 635CrossRefPubMedGoogle Scholar
  15. Hao HD, He LR (2004) Mechanisms of cardiovascular protection by resveratrol. J Med Food 7(3):290–298CrossRefPubMedGoogle Scholar
  16. Ichiyama T, Kajimoto M, Suenaga N, Maeba S, Matsubara T, Furukawa S (2006) Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis. J Neuroimmunol 172(1–2):182–186CrossRefPubMedGoogle Scholar
  17. Khan M, Dhammu TS, Sakakima H, Shunmugavel A, Gilg AG, Singh AK, Singh I (2012) The inhibitory effect of S-nitrosoglutathione on blood–brain barrier disruption and peroxynitrite formation in a rat model of experimental stroke. J Neurochem 123(Suppl 2):86–97CrossRefPubMedCentralPubMedGoogle Scholar
  18. Lee H, Park JW, Kim SP, Lo EH, Lee SR (2009) Doxycycline inhibits matrix metalloproteinase-9 and laminin degradation after transient global cerebral ischemia. Neurobiol Dis 34(2):189–198CrossRefPubMedGoogle Scholar
  19. Lin YL, Chang HC, Chen TL, Chang JH, Chiu WT, Lin JW, Chen RM (2010) Resveratrol protects against oxidized LDL-induced breakage of the blood-brain barrier by lessening disruption of tight junctions and apoptotic insults to mouse cerebrovascular endothelial cells. J Nutr 140(12):2187–2192CrossRefPubMedGoogle Scholar
  20. Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11:1696–1701CrossRefPubMedGoogle Scholar
  21. Marchal J, Pifferi F, Aujard F (2013) Resveratrol in mammals: effects on aging biomarkers, age-related diseases, and life span. Ann N Y Acad Sci 1290(1):67–73CrossRefPubMedGoogle Scholar
  22. Olas B, Saluk-Juszczak J, Wachowicz B (2008) D-glucaro 1,4-lactone and resveratrol as antioxidants in blood platelets. Cell Biol Toxicol 24(2):189–199CrossRefPubMedGoogle Scholar
  23. Rahal K, Schmiedlin-Ren P, Adler J, Dhanani M, Sultani V, Rittershaus AC, Reingold L, Zhu J, McKenna BJ, Christman GM, Zimmermann EM (2012) Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn’s disease. Inflamm Bowel Dis 18(4):613–623CrossRefPubMedCentralPubMedGoogle Scholar
  24. Raval AP, Lin HW, Dave KR, Defazio RA, Della MD, Kim EJ, Perez-Pinzon MA (2008) Resveratrol and ischemic preconditioning in the brain. Curr Med Chem 15(15):1545–1551CrossRefPubMedGoogle Scholar
  25. Rosenberg GA (2002) Matrix metalloproteinases in neuroinflammation. Glia 39(3):279–291CrossRefPubMedGoogle Scholar
  26. Rosenberg GA, Estrada EY, Dencoff JE (1998) Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29(10):2189–2195CrossRefPubMedGoogle Scholar
  27. Saha A, Sarkar C, Singh SP, Zhang Z, Munasinghe J, Peng S, Chandra G, Kong E, Mukherjee AB (2012) The blood-brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol. Hum Mol Genet 21(10):2233–2244CrossRefPubMedCentralPubMedGoogle Scholar
  28. Sakata Y, Zhuang H, Kwansa H, Koehler RC, Dore S (2010) Resveratrol protects against experimental stroke: putative neuroprotective role of heme oxygenase 1. Exp Neurol 224(1):325–329CrossRefPubMedCentralPubMedGoogle Scholar
  29. Shao AW, Wu HJ, Chen S, Ammar AB, Zhang JM, Hong Y. (2013) Resveratrol attenuates early brain injury after subarachnoid hemorrhage through inhibition of NF-kappaB-dependent inflammatory/MMP-9 pathway. CNS Neurosci TherGoogle Scholar
  30. Siflinger-Birnboim A, Del VP, Cooper JA, Blumenstock FA, Shepard JM, Malik AB (1987) Molecular sieving characteristics of the cultured endothelial monolayer. J Cell Physiol 132(1):111–117CrossRefPubMedGoogle Scholar
  31. Souvenir R, Fathali N, Ostrowski RP, Lekic T, Zhang JH, Tang J (2011) Tissue inhibitor of matrix metalloproteinase-1 mediates erythropoietin-induced neuroprotection in hypoxia ischemia. Neurobiol Dis 44(1):28–37CrossRefPubMedCentralPubMedGoogle Scholar
  32. Stetler-Stevenson WG (2008) Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1(27):e6CrossRefGoogle Scholar
  33. Tan HK, Heywood D, Ralph GS, Bienemann A, Baker AH, Uney JB (2003) Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol Cell Neurosci 22(1):98–106CrossRefPubMedGoogle Scholar
  34. Wang X, Barone FC, White RF, Feuerstein GZ (1998) Subtractive cloning identifies tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) increased gene expression following focal stroke. Stroke 29(2):516–520CrossRefPubMedGoogle Scholar
  35. Woo MS, Park JS, Choi IY, Kim WK, Kim HS (2008) Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J Neurochem 106(2):770–780CrossRefPubMedGoogle Scholar
  36. Xiong L, Zheng Y, Wu M, Hou L, Zhu Z, Zhang X, Lu Z (2003) Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral ischemia in rats. Anesth Analg 96(1):233–237PubMedGoogle Scholar
  37. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2):178–201CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Haidong Wei
    • 1
  • Shiquan Wang
    • 2
  • Luming Zhen
    • 1
  • Qianzi Yang
    • 2
  • Zhixin Wu
    • 2
  • Xiaoming Lei
    • 1
  • Jianrui Lv
    • 1
  • Lize Xiong
    • 2
    Email author
  • Rongliang Xue
    • 1
    Email author
  1. 1.Department of AnesthesiologyThe Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’anChina
  2. 2.Department of AnesthesiologyXijing Hospital, Fourth Military Medical UniversityXi’anChina

Personalised recommendations